Pfizer’s Tranquillo Vitiligo Trial Nears Key Data Phase, Setting Up a New Dermatology Catalyst for PFE

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer Inc. (PFE) is running a late-stage study called Tranquillo to test an oral drug for a common skin condition called nonsegmental vitiligo. The study aims to see if the drug can safely restore skin color in adults and teens over 52 weeks, which could open a new market in dermatology if results are strong.

The treatment is ritlecitinib, a once-daily oral capsule designed to target immune pathways that may drive loss of skin pigment. A matching placebo capsule is used as a control, letting researchers see the true effect of the active drug.

The study is a Phase 3 trial where participants are randomly assigned to either ritlecitinib or placebo. It uses a double-blind setup, so patients, doctors, and study staff do not know who gets which treatment, and the main goal is to test how well the drug treats vitiligo.

The trial started in October 2022 and ran for 52 weeks of treatment and follow-up to track both benefits and side effects. The study is now listed as completed, and the most recent update on February 25, 2026 signals that key data review steps are underway.

For investors, a completed Phase 3 trial in a visible condition like vitiligo could be a growth driver if results are positive and support future approval. Success would help PFE expand its immunology and dermatology footprint and compete with players working on similar immune-based skin treatments.

Market sentiment may turn more upbeat as investors anticipate headline data and potential regulatory filings from this program. While final numbers are not yet posted, the updated study status suggests a clear path toward the next catalysts for PFE’s stock.

The ritlecitinib vitiligo study is now completed and recently updated, with more detailed information available on the ClinicalTrials portal.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.